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ill population has been difﬁcult. OBJECTIVES: To explore 
protective and risk factors for a later severe violent offense 
(i.e. forensic admission) among the mentally ill (schizophrenics)
and to do thorough investigation for appropriate models.
METHODS: Between 1998–2000, 308 forensic and general psy-
chiatry patients were recruited to case-control study in Canada,
Finland, Germany, and Sweden. An innovative greedy naive
Bayesian (NB) algorithm P-Course was utilized to search gener-
alized factors from national datasets into a merger model (naive
Bayesian fusion). The evidence was assessed with posterior odds
(PO) and the predictions with accuracy, diagnostic odds ratio
(DOR), area under ROC curve (AUC), Gini coefﬁcient and log-
arithmic loss (log score). The models were tested using leave-one-
out cross-validations and substitution procedures in which data
was divided into separate teaching and test sets. RESULTS: The
most inﬂuential predictive risk factors for violent offence include
violent behavior prior to the index hospitalization (PO 11.8;
95% credibility interval 5.9–30.3), biological father’s conviction
(9.4; 4.7–20.0), no use of psychotropic medications before the
age of 18 (7.7; 4.3–16.5), and biological father’s substance abuse
(2.6; 1.7–4.1). The merger model indicates very good discrimi-
native power (DOR from 30.25; AUC from 0.82; Gini from
0.63; log score below 0.65) as well as robustness and accuracy
(Canadian 82.5%; Swedish 87.1%) for the test sets. CONCLU-
SIONS: The characteristics of biological father and no use of psy-
chopharmaceuticals before the age of 18 among mentally ill were
related to committing a later severe violent offense. The explo-
ration and predictions were carried out with P-Course and the
multinational merger NB model indicated high discriminatory
power and robustness compared to previous studies.
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OBJECTIVES: While the prescription of SSRIs and SNRIs for
major depressive disorder (MDD) has increased, resource utili-
sation has rarely been studied in large populations in real-life set-
tings. The purpose of this study was to assess resource utilisation
associated with the prescription of antidepressants in an adult
population with MDD in primary care using data extracted 
from the General Practitioner Research Database (GPRD).
METHODS: We conducted a retrospective study using the
GPRD. Patients diagnosed with MDD aged 18–70 having a new
prescription of paroxetine, ﬂuoxetine, citalopram, sertraline, esc-
italopram, venlafaxine or amitriptyline between January 1, 2001
and September 30, 2003 and not having received antidepressant
treatment in the previous six-months were included. Analyses
focused on ﬁrst depressive episodes for each patient. Patient,
disease and treatment characteristics, GP visits, referrals and hos-
pitalisations were analysed. RESULTS: Information was gath-
ered from over 59,000 patients. Mean age of patients was 39
and 69% were female. 57% suffered from mild depression, 37%
moderate and 6% severe. Mean time of a depressive episode was
about 6 months. Patients visited a GP on average 10 times per
episode. There was a trend between frequency of GP visits and
severity per episode (10 for mild, 11 for moderate and 12 for
severe). 2% of patients were referred to psychiatric specialists.
Compared with patients under SSRIs, there were 80% more
referrals under SNRIs and 20% fewer under TCAs. 4% of all
patients were hospitalized: 60% more hospitalisations under
SNRIs and 40% more under TCAs compared with SSRIs. CON-
CLUSIONS: This GPRD-based study provides better knowledge
of medical resource use in depressed patients in the UK. It should
promote better prescription strategies and use of antidepressants
in primary care.
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OBJECTIVES: To assemble data on resource use for patients
with schizophrenia across several European countries.
METHODS: Physicians in 5 European countries who prescribed
antipsychotics for ≥15 patients with schizophrenia within the
preceding 3 months were invited to complete a questionnaire
concerning their patients’ clinical status and resource use.
Resource use was assessed in terms of frequency of psychiatric
hospitalization, length of last completed hospital stay, intensive
care unit use, outpatient visits, and number of current medica-
tions. RESULTS: Data were obtained from 704 physicians treat-
ing 6569 patients from France (n = 1492), Germany (n = 1439),
Italy (n = 1003), Spain (n = 1310), and the UK (n = 1326). Italy
(77%), Spain (75%), and Germany (72%) had larger percent-
ages of patients with at least one psychiatric hospitalization in
the previous year than did France (56%) and the UK (55%).
Mean length of hospital stay varied signiﬁcantly across countries,
from 19.4 days in Italy to 67.5 days in the UK, and was signif-
icantly longer for the subset of patients in whom negative symp-
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toms predominated (n = 621; 9.5%) than in the full study pop-
ulation (56.3 vs 50.6 days; P < 0.05). Mean number of outpa-
tient visits related to schizophrenia in the previous 12 months
ranged from 3.8 in the UK to 10.8 in France. Mean number of
medications per patient ranged from 1.4 in the UK to 1.9 in
France. Compared with the entire study population, patients
with predominant negative symptoms had more frequent outpa-
tient visits (mean, 8.7 vs 7.9; P < 0.05), fewer emergency depart-
ment visits (mean, 0.5 vs 0.7; P < 0.01), and no difference in
number of medications taken (mean, 0.9 vs 0.9). CONCLU-
SIONS: Resource use in this large, retrospective sample of
patients varied across countries and with the presence or absence
of predominant negative symptoms.
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OBJECTIVES: To identify published studies of the cost-effec-
tiveness of cognitive-behavioural therapy (CBT) for the treat-
ment of mental illness, and to review its health economic
evidence base. METHODS: PubMed, Embase, Psych Info data-
bases (1985–2005; English, French and Spanish) were searched
to identify formal cost-effectiveness analyses of CBT using key-
words: cognitive-behavioural therapy, interpersonal therapy,
counseling, psychoanalysis, anxiety, obsessive-compulsive disor-
der, depression, depressive disorder, post-traumatic stress disor-
der, social phobia, bipolar disorder, personality disorder, eating
disorder, psychosis, costs, cost analysis, cost-effectiveness, and
economic. RESULTS: Of 531 abstracts reviewed, 13 cost-effec-
tiveness studies were identiﬁed. CBT alone or in combination
with medication, was shown to be cost-effective across countries
(Australia = 5; USA = 5; UK = 3), and patient populations (mood
disorders = 8; anxiety disorders = 4; psychosis = 1), regardless
of study design or effectiveness outcome employed. Reported
cost-effectiveness ratios (CERS) and incremental CERs were uni-
formly well below accepted thresholds. Generally, CBT added to
usual care contributed little incremental cost due to offsets from
reduced health care utilization. Limitations of these analyses
include the omission of training and start-up expenditures, the
exclusion of indirect costs (lost productivity), relatively short
time horizons employed, and variability of response and remis-
sion rates. Despite compelling clinical and economic evidence,
CBT remains underutilized. Barriers to more widespread use
include restrictive mental health funding policy for non-
pharmacological treatments, and lack of accredited CBT practi-
tioners. CONCLUSIONS: Internationally, CBT represents good
value for health dollars spent. Increased utilization of CBT for
mental health disorders would improve clinical outcomes and
could result in reduced health care expenditures. Further
research to better understand long-term clinical and economic
outcomes of CBT is warranted.
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OBJECTIVE: To develop an evidenced-based clinical pathway
for schizophrenia and to evaluate its effectiveness. METHODS:
A multidisciplinary team was formed. We identiﬁed the processes
of the care provided and we identiﬁed its possible pitfalls. Then
we re-designed the care according to a clinical pathway includ-
ing the best evidences. To evaluate the impact of the pathway we
used process indicators (variation rates in drugs patterns, rate of
compliance to the personal management plan, quality of the clin-
ical records), outcome indicators (mental tests and rate of job re-
insert, rate of revolving doors, hospital admission) and sentinel
events (rate of adverse drug reactions). We performed a concur-
rent controlled trial to compare the results obtained treating the
patients according to the clinical pathway and treating the
patients according to the current practice. We used t-test for 
continuous variables and X2 test for qualitative variables.
RESULTS: The pathway has been in use for 3 months (expected
12) and 36 patients were treated (19 cases and 17 controls). The
implementation of the pathway helped to re-organize 10 clinical
and organizational procedures in the care of schizophrenia,
including labs and drugs prescription. We observed an improve-
ment in the ﬁlling up of the personal management plan (38.46%
cases vs. 0% controls; p = 0.005), in the use of mental tests
(35.56% vs. 0%; p = 0.006) and a reduction in patients’ physi-
cal contention (16.67% vs. 69.23%; p = 0.04). Moreover we
observed a signiﬁcant reduction in the use of anti psychotic drugs
(16.67% vs. 69.23%; p = 0.04) and of depot therapy (16.67%
vs. 60%; p = 0.01), with a prescription pattern more consistent
to the evidences. CONCLUSIONS: Even though our results are
still preliminary we think that the implementation of the clinical
pathway improved the quality of the process of care.
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OBJECTIVES: We examined the association of acute hospital-
ization use by the elderly with psychiatric morbidity and social
equity in health care access, taking into account other predis-
posing, need and enabling factors, in Singapore. METHODS:
Population-based data from national representative sample (N =
1092) of older adults aged ≥60 in Singapore were used to iden-
tify subjects ≥ one acute hospitalization in 12 months prior to
interview (N = 136). The associations of acute hospitalization
with socio-economic, medical and psychiatric morbidity, health,
functional status and behavioral variables were evaluated in mul-
tivariate models with adjusted odds ratio (OR). RESULTS: Hos-
pitalization use was independently associated with “being retired
or unemployed” (OR,3.15;95%cl,1.30–7.63), ≥2 medical con-
ditions (OR,2.88;95%cl,1.66–4.99), SF-12 PCS scores of physi-
cal health status (middle tertile, OR,0.39;95%cl,0.23–0.66;
highest tertile,OR,0.37;95%cl,0.20–0.67; versus lowest tertile),
regular visiting of primary health care provider (OR,1.92;
95%cl,1.10–3.36), and co-morbid psychiatric disorder (OR,
2.76;95%cl,1.20–6.33). Proxy social equity indicators of health
care access including self-reported ﬁnancial limitation to pay for
needed health care were not associated with hospitalization use.
CONCLUSIONS: Acute hospitalization use by the elderly was
related to psychiatric morbidity, and apparently un-related to
potential social inequity in access to the health care system in
Singapore. The complex relationships between psychiatric mor-
bidity and medical and psychosocial factors and hospitalization
in the elderly require further studies.
